ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.70
0.00 (0.00%)
As of 12:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.70
Open3.70
Bid3.70 x 800
Ask3.75 x 1400
Day's Range3.70 - 3.78
52 Week Range1.55 - 5.75
Volume226,529
Avg. Volume664,507
Market Cap224.22M
Beta2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateOct 30, 2017 - Nov 3, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
Trade prices are not sourced from all markets
  • AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA™
    PR Newswire9 days ago

    AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA™

    DSUVIA Advisory Committee meeting date set for October 12, 2018 REDWOOD CITY, Calif. , Sept. 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical ...

  • Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
    Zacks15 days ago

    Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?

    Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

  • AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
    PR Newswire28 days ago

    AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September

    REDWOOD CITY, Calif. , Aug. 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of ACRX earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 AcelRx Pharmaceuticals Inc Earnings Call

  • GlobeNewswire29 days ago

    New Research: Key Drivers of Growth for OncoSec Medical, AcelRx Pharmaceuticals, Cameco, Prestige Brand, Berry Global Group, and A-Mark Precious Metals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OncoSec ...

  • AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium
    PR Newswirelast month

    AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium

    REDWOOD CITY, Calif. , Aug. 20, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...

  • Benzingalast month

    AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation

    The company's lead candidate Dsuvia, a 30mcg sufentanil NanoTab placed sublingually by a health care professional via a single-dose applicator, is being touted as a substitute for intravenous opioids, currently the gold standard to treat moderate-to-severe pain in emergency departments, Higgins said in a Thursday note.

  • Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
    Zackslast month

    Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?

    Is (ACRX) Outperforming Other Medical Stocks This Year?

  • AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswirelast month

    AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

    REDWOOD CITY, Calif., Aug. 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common stock. Including this option exercise, total gross proceeds to AcelRx from the offering of an aggregate 8,363,636 shares at a price to the public of $2.75 per share were approximately $23.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by AcelRx. Ladenburg Thalmann acted as co-manager for the offering.

  • AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks2 months ago

    AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

    AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.26% and -11.57%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    AcelRx Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 20 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results

    - European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings - June 30, 2018 cash and short-term ...

  • ACCESSWIRE2 months ago

    AcelRx Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
    Zacks2 months ago

    CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

    CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

  • AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
    PR Newswire2 months ago

    AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018

    REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results ...

  • ACCESSWIRE2 months ago

    Free Technical Research on Medtronic and Three More Medical Equipment Equities

    On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), and MiMedx Group Inc. (NASDAQ: MDXG).

  • Why You Shouldn’t Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock
    SmarterAnalyst2 months ago

    Why You Shouldn’t Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock

    Not everyone is excited about AcelRx Pharmaceuticals (NASDAQ:ACRX), which focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. Despite the potential advantages, Oppenheimer analyst Leland Gershell believes the drug maker's products may face challenges with market penetration given: (1) the broad effort to reduce opioids' dominant role in analgesia, (2) the unclear advantage of needle-free delivery in populations who typically get IV access, and (3) the lack of physician familiarity with their active ingredient. Anesthesiologists and other specialists we have spoken with agree that Dsuvia could find some utility for acute pain management, and highlight the palliative care setting (e.g. AcelRx's acute pain drug Dsuvia has a November 3, 2018 FDA action date, in advance of which management expects the agency to hold an Advisory Committee meeting.

  • AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    PR Newswire2 months ago

    AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    REDWOOD CITY, Calif., July 12, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 7,272,727 shares of its common stock, at a public offering price of $2.75 per share. The gross proceeds to AcelRx from this offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx, are expected to be approximately $20 million.  All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about July 16, 2018, subject to the satisfaction of customary closing conditions.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...

  • AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock
    PR Newswire2 months ago

    AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock

    REDWOOD CITY, Calif., July 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it has commenced an underwritten public offering of shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  All of the shares to be sold in the proposed offering will be sold by AcelRx. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.  H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

  • Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
    Zacks2 months ago

    Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

    Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

  • VIVUS' PAH Candidate Data Positive in Early Stage Study
    Zacks2 months ago

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

  • Aclaris' Alopecia Candidate Gets Fast Track Designation
    Zacks2 months ago

    Aclaris' Alopecia Candidate Gets Fast Track Designation

    The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

  • Why this Peninsula drug company still is betting on pain for a gain
    American City Business Journals3 months ago

    Why this Peninsula drug company still is betting on pain for a gain

    FDA regulators rejected its drug-device in October, sending its stock sharply lower. Now this company believes new data, Defense Department and hospital shortages of painkillers could help it score approval in November like it did in Europe last month.

  • AcelRx receives European Commission approval for DZUVEO™
    PR Newswire3 months ago

    AcelRx receives European Commission approval for DZUVEO™

    REDWOOD CITY, Calif., June 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) has approved DZUVEO (under development in the U.S. as DSUVIA™) for the management of acute moderate to severe pain in adults in medically monitored settings.